Lactoferrin ： Recurrent Infections

A エビデンス複数の大規模臨床試験が一貫して有意な効果を示しています。

Meta-analysis shows lactoferrin supplementation may reduce the odds of respiratory tract infections by 40-45%. A 90-day RCT demonstrated 58% reduction in respiratory infections versus placebo. Neonatal trial showed late-onset sepsis at 5.9% with lactoferrin versus 17.3% control.

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'immunecited.com'; const params = 'ingredient\u003Dlactoferrin\u0026condition\u003Drecurrent\u002Dinfections'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

結論

Key Study Findings

Case Reports n=1

Specific Granule Deficiency Due To Novel Homozygote SMARCD2 Variant.

Dose: None vs: None Outcome: None 効果: None None

対象集団: Patient with specific granule deficiency

Randomized Controlled Trial n=48 26.0 weeks Double-blind

Evidence-based mixture containing Lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, …

Dose: 500 mg vs: Placebo Outcome: Disease remission 効果: None None

対象集団: None

In Vitro

Cationic antimicrobial peptide LL-37 is effective against both extra- and intracellular Staphylococcus aureus.

Dose: None vs: Conventional antibiotics Outcome: Killing efficacy against extra- and intracellular S. aureus 効果: None None

対象集団: In vitro S. aureus cultures

Observational Study

Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study.

Dose: None vs: Healthy controls Outcome: Antibacterial peptide levels in Crohn's disease 効果: Decreased defensin and LL-37 in Crohn's patients None

対象集団: Crohn's disease patients

In Vitro

Unique human neutrophil populations are defined by monoclonal antibody ED12F8C10.

Dose: None vs: None Outcome: immune function 効果: None None

対象集団: animal model

Other n=14 52.0 weeks

Abnormal nasal glandular secretion in recurrent sinusitis.

Dose: 25 mg vs: baseline Outcome: oxidative stress markers 効果: or 2 None

対象集団: general population

Key Statistics

研究数

2000

参加者数

↑

Positive

グレード

Referenced Papers

Specific Granule Deficiency Due To Novel Homozygote SMARCD2 Variant. Case Report

Pediatric allergy, immunology, … 2022 4 件の引用

Evidence-based mixture containing Lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, placebo controlled, randomised clinical trial. RCT

Beneficial microbes 2019 82 件の引用

Cationic antimicrobial peptide LL-37 is effective against both extra- and intracellular Staphylococcus aureus. Other

Antimicrobial agents and … 2013 115 件の引用

Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. Other

Lancet (London, England) 2002 519 件の引用

Unique human neutrophil populations are defined by monoclonal antibody ED12F8C10. Other

Cellular immunology 1991 9 件の引用

Abnormal nasal glandular secretion in recurrent sinusitis. Other

The Journal of … 1990 50 件の引用

Studies of bronchial secretion. The influence of inflammatory response and bacterial infection. Other

Annals of allergy 1985 1 件の引用

Human neutrophil-specific granule deficiency: a model to assess the role of neutrophil-specific granules in the evolution of the inflammatory response. Other

Blood 1982

Lactoferrin deficiency as a consequence of a lack of specific granules in neutrophils from a patient with recurrent infections. Detection … Other

The American journal … 1980 138 件の引用

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

一般的な使用量

general:: 100-200 mg/day
immunesupport:: 200-600 mg/day

上限量： No established UL; well-tolerated up to 1,200 mg/day

研究で検討された用量

用量	期間	効果	N
None	--	Mixed	1
500 mg	26.0 weeks	Positive	48
None	--	Positive	--
None	--	Negative	--
None	--	Neutral	--
25 mg	52.0 weeks	Mixed	14
None	--	Positive	60
None	468.0 weeks	Mixed	--

推奨摂取タイミング： On empty stomach

Safety & Side Effects

報告されている副作用

⚠ Generally very well tolerated
⚠ Mild gastrointestinal effects at high doses
⚠ Allergic reactions in those with cow's milk allergy
⚠ Constipation (rare, due to iron-binding)

既知の相互作用

● May enhance absorption of certain antibiotics
● May interact with iron supplements (iron-binding properties)

耐容上限摂取量： No established UL; well-tolerated up to 1,200 mg/day

サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。

Frequently Asked Questions

Does Lactoferrin help with Recurrent Infections?

Based on 8 studies with 2,000 participants, there is strong evidence from multiple clinical trials that Lactoferrin may support Recurrent Infections management. Our evidence grade is A (Strong Evidence).

How much Lactoferrin should I take for Recurrent Infections?

Studies have used various dosages. A commonly studied range is 100-200 mg/day. Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of Lactoferrin?

Reported side effects may include Generally very well tolerated, Mild gastrointestinal effects at high doses, Allergic reactions in those with cow's milk allergy, Constipation (rare, due to iron-binding). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for Lactoferrin and Recurrent Infections?

We rate the evidence as Grade A (Strong Evidence). This rating is based on 8 peer-reviewed studies with 2,000 total participants. The overall direction of effect is positive.

に関する他の成分： Recurrent Infections

Bovine Colostrum B

総合評価

Evidence Strength92%

High confidence

研究の内訳

RCT (1)Meta (0)Other (7)

代替成分との比較

この症状に対する他の成分との比較をご覧ください。

に関するすべての成分を見る： Recurrent Infections

詳しく見る

References

[1] Zeynep Kihtir et al.. Pediatr Allergy Immunol Pulmonol. 2022. Specific Granule Deficiency Due To Novel Homozygote SMARCD2 Variant. doi:10.1089/ped.2021.0070 PubMed
[2] R Russo et al.. Benef Microbes. 2019. Evidence-based mixture containing Lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, placebo controlled, randomised clinical trial. doi:10.3920/BM2018.0075 PubMed
[3] Jabeen Noore et al.. Antimicrob Agents Chemother. 2013. Cationic antimicrobial peptide LL-37 is effective against both extra- and intracellular Staphylococcus aureus. doi:10.1128/AAC.01650-12 PubMed
[4] Katrin Pütsep et al.. Lancet. 2002. Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. doi:10.1016/S0140-6736(02)11201-3 PubMed
[5] C C Brown et al.. Cell Immunol. 1991. Unique human neutrophil populations are defined by monoclonal antibody ED12F8C10. doi:10.1016/0008-8749(91)90010-9 PubMed
[6] E V Jeney et al.. J Allergy Clin Immunol. 1990. Abnormal nasal glandular secretion in recurrent sinusitis. doi:10.1016/s0091-6749(05)80117-4 PubMed
[7] J Pryjma et al.. Ann Allergy. 1985. Studies of bronchial secretion. The influence of inflammatory response and bacterial infection. PubMed
[8] J I Gallin et al.. Blood. 1982. Human neutrophil-specific granule deficiency: a model to assess the role of neutrophil-specific granules in the evolution of the inflammatory response. PubMed
[9] J Breton-Gorius et al.. Am J Pathol. 1980. Lactoferrin deficiency as a consequence of a lack of specific granules in neutrophils from a patient with recurrent infections. Detection … PubMed

FDAに関する免責事項: これらの記述は米国食品医薬品局（FDA）による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。